These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27784746)

  • 1. CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α.
    Tian X; Nguyen M; Foote HP; Caster JM; Roche KC; Peters CG; Wu P; Jayaraman L; Garmey EG; Tepper JE; Eliasof S; Wang AZ
    Cancer Res; 2017 Jan; 77(1):112-122. PubMed ID: 27784746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis.
    Lin CJ; Lin YL; Luh F; Yen Y; Chen RM
    Oncotarget; 2016 Jul; 7(27):42408-42421. PubMed ID: 27285755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer.
    Conley SJ; Baker TL; Burnett JP; Theisen RL; Lazarus D; Peters CG; Clouthier SG; Eliasof S; Wicha MS
    Breast Cancer Res Treat; 2015 Apr; 150(3):559-67. PubMed ID: 25833208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.
    Pham E; Yin M; Peters CG; Lee CR; Brown D; Xu P; Man S; Jayaraman L; Rohde E; Chow A; Lazarus D; Eliasof S; Foster FS; Kerbel RS
    Cancer Res; 2016 Aug; 76(15):4493-503. PubMed ID: 27325647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer.
    Pham E; Birrer MJ; Eliasof S; Garmey EG; Lazarus D; Lee CR; Man S; Matulonis UA; Peters CG; Xu P; Krasner C; Kerbel RS
    Clin Cancer Res; 2015 Feb; 21(4):808-18. PubMed ID: 25524310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer.
    Sanoff HK; Moon DH; Moore DT; Boles J; Bui C; Blackstock W; O'Neil BH; Subramaniam S; McRee AJ; Carlson C; Lee MS; Tepper JE; Wang AZ
    Nanomedicine; 2019 Jun; 18():189-195. PubMed ID: 30858085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer.
    Gaur S; Wang Y; Kretzner L; Chen L; Yen T; Wu X; Yuan YC; Davis M; Yen Y
    Nanomedicine; 2014 Oct; 10(7):1477-86. PubMed ID: 24768630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle.
    Eliasof S; Lazarus D; Peters CG; Case RI; Cole RO; Hwang J; Schluep T; Chao J; Lin J; Yen Y; Han H; Wiley DT; Zuckerman JE; Davis ME
    Proc Natl Acad Sci U S A; 2013 Sep; 110(37):15127-32. PubMed ID: 23980155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.
    Keefe SM; Hoffman-Censits J; Cohen RB; Mamtani R; Heitjan D; Eliasof S; Nixon A; Turnbull B; Garmey EG; Gunnarsson O; Waliki M; Ciconte J; Jayaraman L; Senderowicz A; Tellez AB; Hennessy M; Piscitelli A; Vaughn D; Smith A; Haas NB
    Ann Oncol; 2016 Aug; 27(8):1579-85. PubMed ID: 27457310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer.
    Gaur S; Chen L; Yen T; Wang Y; Zhou B; Davis M; Yen Y
    Nanomedicine; 2012 Jul; 8(5):721-30. PubMed ID: 22033079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction: CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1
    Cancer Res; 2017 Dec; 77(23):6790-6791. PubMed ID: 29196418
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.
    Voss MH; Hussain A; Vogelzang N; Lee JL; Keam B; Rha SY; Vaishampayan U; Harris WB; Richey S; Randall JM; Shaffer D; Cohn A; Crowell T; Li J; Senderowicz A; Stone E; Figlin R; Motzer RJ; Haas NB; Hutson T
    Ann Oncol; 2017 Nov; 28(11):2754-2760. PubMed ID: 28950297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.
    Svenson S; Wolfgang M; Hwang J; Ryan J; Eliasof S
    J Control Release; 2011 Jul; 153(1):49-55. PubMed ID: 21406204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101.
    Ng TS; Wert D; Sohi H; Procissi D; Colcher D; Raubitschek AA; Jacobs RE
    Clin Cancer Res; 2013 May; 19(9):2518-27. PubMed ID: 23532891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin as an Alternative Radiosensitizing Agent to 5-Fluorouracil During Neoadjuvant Treatment for Rectal Cancer.
    Fernandes JM; Jandrey EHF; Koyama FC; Leite KRM; Camargo AA; Costa ÉT; Perez RO; Asprino PF
    Dis Colon Rectum; 2020 Jul; 63(7):918-926. PubMed ID: 32229782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer.
    Nagaraju GP; Farran B; Farren M; Chalikonda G; Wu C; Lesinski GB; El-Rayes BF
    Cancer; 2020 Jul; 126(14):3360-3371. PubMed ID: 32383803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing.
    Clark AJ; Wiley DT; Zuckerman JE; Webster P; Chao J; Lin J; Yen Y; Davis ME
    Proc Natl Acad Sci U S A; 2016 Apr; 113(14):3850-4. PubMed ID: 27001839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of olaparib and camptothecin for effective radiosensitization.
    Miura K; Sakata K; Someya M; Matsumoto Y; Matsumoto H; Takahashi A; Hareyama M
    Radiat Oncol; 2012 Apr; 7():62. PubMed ID: 22524618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
    Krasner CN; Campos SM; Young CL; Chadda KR; Lee H; Birrer MJ; Horowitz NS; Konstantinopoulos PA; D'Ascanio AM; Matulonis UA; Penson RT
    Gynecol Oncol; 2021 Sep; 162(3):661-666. PubMed ID: 34243976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.